ru-66647 has been researched along with Diabetes-Mellitus* in 2 studies
2 other study(ies) available for ru-66647 and Diabetes-Mellitus
Article | Year |
---|---|
Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system.
We developed a semi-automated active monitoring system that uses sequential matched-cohort analyses to assess drug safety across a distributed network of longitudinal electronic health-care data. In a retrospective analysis, we show that the system would have identified cerivastatin-induced rhabdomyolysis. In this study, we evaluated whether the system would generate alerts for three drug-outcome pairs: rosuvastatin and rhabdomyolysis (known null association), rosuvastatin and diabetes mellitus, and telithromycin and hepatotoxicity (two examples for which alerting would be questionable). Over >5 years of monitoring, rate differences (RDs) in comparisons of rosuvastatin with atorvastatin were -0.1 cases of rhabdomyolysis per 1,000 person-years (95% confidence interval (CI): -0.4, 0.1) and -2.2 diabetes cases per 1,000 person-years (95% CI: -6.0, 1.6). The RD for hepatotoxicity comparing telithromycin with azithromycin was 0.3 cases per 1,000 person-years (95% CI: -0.5, 1.0). In a setting in which false positivity is a major concern, the system did not generate alerts for the three drug-outcome pairs. Topics: Aged; Anti-Bacterial Agents; Azithromycin; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Drug Monitoring; Electronic Data Processing; Electronic Health Records; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ketolides; Male; Outcome Assessment, Health Care; Product Surveillance, Postmarketing; Retrospective Studies; Rhabdomyolysis | 2012 |
Pharmacokinetic interaction between telithromycin and metformin in diabetes mellitus rats.
Telithromycin and metformin have been reported to be commonly metabolized via hepatic CYP3A1/2 in rats. Community-acquired respiratory tract infection was reported to be frequent in patients with diabetes mellitus. Compared with controls, hepatic CYP3A1/2 was reported to be increased in male rats with diabetes mellitus induced by streptozotocin (DMIS rats). After the intravenous administration of both drugs together to male DMIS rats, the time-averaged non-renal clearance (CL(NR)) of metformin was significantly slower (by 33.1%; 10.3 versus 15.4 ml min(-1) kg(-1)) than metformin alone due to the inhibition of hepatic metabolism of metformin by telithromycin via CYP3A1/2. After the oral administration of both drugs together, the total area under the plasma concentration-time curve (AUC) of metformin was comparable possibly due to the increased intestinal metabolism of metformin by telithromycin. Topics: Administration, Oral; Animals; Blood Proteins; Diabetes Mellitus; Dialysis; Drug Interactions; Injections, Intravenous; Intestinal Mucosa; Ketolides; Male; Metformin; Microsomes, Liver; Protein Binding; Rats; Rats, Sprague-Dawley | 2010 |